Abstract
The new 6th edition of this respected management report is the essential
reference work for everyone in the field. The report covers 121 companies -
from the largest blue-chip multinational to smaller specialist organisations -
and all phases of development from research to launched products.
Detailed analysis of the structure, performance and research of leading cancer drug development companies.
By 2012, the global cancer market is expected to generate revenues in excess
of US$65 billion due to growth in the sales of existing products and the
launch of nearly 60 new products, which will account for around 30% of total
drug launches. These will offset the decline in sales of cytotoxics and
antihormonals, which face generic competition and the uptake of newer products
in preference to these older agents.
The cancer treatment market is set to change radically as newer targeted
therapies replace broader spectrum treatments. They are generally better
tolerated, less toxic and provide better patient outcomes. A trend also to be
noted is the rise of combination therapies and earlier drug intervention,
often at the surgical stage. Against these positive trends is a growing
concern about the rising cost of cancer drugs. With several products now
costing US$10,000+, the balance of meeting medical demands against the cost of
treatment is an issue in all developed countries.
In the challenging cancer therapeutic market, which companies have the products, research and thinking that will shape the future market?
The new updated and expanded 6th edition of this highly respected management
report, Who' s Developing What in New Cancer Drugs 2007? is the
essential reference work for everyone in the field. The report covers 121
companies - from the largest blue-chip multinational to smaller specialist
organisations - and all phases of development from research to launched
products.
Competition for market voice, valuable licensing deals and funding is fierce in a sector characterised by novel research and the promise of significant clinical benefits and commercial return.
Cancer continues to dominate industry research and investment as the search
for really effective therapies hots up. The commercial rewards for companies
that make significant breakthroughs in the cure or control of key cancers such
as breast, ovarian, lung and prostate are considerable.
The application of biotechnology to the identification and development of drug
candidates has seen a variety of novel paths pursued by a range of development
companies.
For analysts, investors and pharmaceutical company executives, being able to
readily and easily assess these companies, the research they are pursuing,
products being developed, collaborators and financial performance/funding is
key to understanding this sector of the pharmaceutical market.
View Cart
